Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma

NCT03530683 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03530683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03530683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
May 14, 2018
Completion date
July 18, 2024
Enrollment
189 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, diffuse large b-cell lymphoma, lymphoma, multiple myeloma